[1] |
KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
doi: 10.1038/s41375-022-01613-1
|
[2] |
HUBER S, HAFERLACH T, MÜLLER H, et al. MDS subclassification-do we still have to count blasts?[J]. Leukemia, 2023, 37(4):942-945.
doi: 10.1038/s41375-023-01855-7
pmid: 36813994
|
[3] |
SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO Classification of Tumours of Haematopoietic and LymphoidTissues[M]. 4th ed.Lyon: IARC, 2017.
|
[4] |
CREE I A. The WHO Classification of Haematolymphoid Tumours[J]. Leukemia, 2022, 36(7):1701-1702.
doi: 10.1038/s41375-022-01625-x
pmid: 35732830
|
[5] |
MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2):157-170.
doi: 10.1182/blood.2020004850
pmid: 32347921
|
[6] |
BERNARD E, NANNYA Y, HASSERJIAN R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10):1549-1556.
doi: 10.1038/s41591-020-1008-z
|
[7] |
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours[M]// WHO classification of tumours series. 5th ed. Lyon (France): International Agency for Research on Cancer, 2022.
|
[8] |
ESTEY E, HASSERJIAN RP, DÖHNER H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal[J]. Blood, 2022, 139(3):323-332.
doi: 10.1182/blood.2021011304
URL
|
[9] |
ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228.
|
[10] |
SOUPIR C P, VERGILIO J A, DAL CIN P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis[J]. Am J Clin Pathol, 2007, 127(4):642-650.
doi: 10.1309/B4NVER1AJJ84CTUU
pmid: 17369142
|
[11] |
TARLOCK K, LAMBLE A J, WANG Y C, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group[J]. Blood, 2021, 138(13):1137-1147.
|
[12] |
GAO Y, JIA M, MAO Y, et al. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia[J]. Am J Clin Pathol, 2022, 157(5):691-700.
doi: 10.1093/ajcp/aqab172
URL
|
[13] |
DI GIACOMO D, LA STARZA R, GORELLO P, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia[J]. Blood, 2021, 138(9):773-784.
doi: 10.1182/blood-2021-150841
URL
|
[14] |
WICK N, HITTO I, WELDER D, et al. Acute myeloid leukemia with RAM immunophenotype presenting with extensive mesenteric and retroperitoneal lymphadenopathy: A case report and review of the literature[J]. Leuk Res Rep, 2021, 17:100287.
|